These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 15950639)

  • 21. Multifollicular recruitment in combination with gonadotropin-releasing hormone antagonist increased pregnancy rates in intrauterine insemination cycles.
    Gómez-Palomares JL; Acevedo-Martín B; Chávez M; Manzanares M; Ricciarelli E; Hernández ER
    Fertil Steril; 2008 Mar; 89(3):620-4. PubMed ID: 17678911
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Minimal stimulation IVF with late follicular phase administration of the GnRH antagonist cetrorelix and concomitant substitution with recombinant FSH: a pilot study.
    Pelinck MJ; Vogel NE; Hoek A; Arts EG; Simons AH; Heineman MJ
    Hum Reprod; 2005 Mar; 20(3):642-8. PubMed ID: 15608031
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comparison of gonadotropin-releasing hormone (GnRH) antagonist and GnRH agonist flare protocols for poor responders undergoing in vitro fertilization.
    Berin I; Stein DE; Keltz MD
    Fertil Steril; 2010 Feb; 93(2):360-3. PubMed ID: 19131055
    [TBL] [Abstract][Full Text] [Related]  

  • 24. GnRH antagonist versus long GnRH agonist protocol in poor responders undergoing IVF: a randomized controlled trial.
    Cheung LP; Lam PM; Lok IH; Chiu TT; Yeung SY; Tjer CC; Haines CJ
    Hum Reprod; 2005 Mar; 20(3):616-21. PubMed ID: 15608037
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of gonadotrophin-releasing hormone (GnRH) antagonist during the LH surge in normal women and during controlled ovarian hyperstimulation.
    Christin-Maitre S; Olivennes F; Dubourdieu S; Chabbert-Buffet N; Charbonnel B; Frydman R; Bouchard P
    Clin Endocrinol (Oxf); 2000 Jun; 52(6):721-6. PubMed ID: 10848876
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early initiation of gonadotropin-releasing hormone antagonist treatment results in a more stable endocrine milieu during the mid- and late-follicular phases: a randomized controlled trial comparing gonadotropin-releasing hormone antagonist initiation on cycle day 2 or 6.
    Hamdine O; Broekmans FJ; Eijkemans MJ; Lambalk CB; Fauser BC; Laven JS; Macklon NS;
    Fertil Steril; 2013 Sep; 100(3):867-74. PubMed ID: 23809501
    [TBL] [Abstract][Full Text] [Related]  

  • 27. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study.
    Humaidan P; Bredkjaer HE; Bungum L; Bungum M; Grøndahl ML; Westergaard L; Andersen CY
    Hum Reprod; 2005 May; 20(5):1213-20. PubMed ID: 15760966
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of low-dose human chorionic gonadotropin (hCG) in a GnRH antagonist protocol.
    Koichi K; Yukiko N; Shima K; Sachiko S
    J Assist Reprod Genet; 2006 May; 23(5):223-8. PubMed ID: 16786420
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of gonadotropin-releasing hormone agonist/recombinant follicle-stimulating hormone versus gonadotropin-releasing hormone antagonist/recombinant follicle-stimulating hormone on follicular fluid levels of adhesion molecules during in vitro fertilization.
    Fornaro F; Cobellis L; Mele D; Tassou A; Badolati B; Sorrentino S; De Lucia D; Colacurci N
    Fertil Steril; 2007 Jan; 87(1):39-47. PubMed ID: 17084393
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of luteal estradiol patch and gonadotropin-releasing hormone antagonist suppression protocol before gonadotropin stimulation versus microdose gonadotropin-releasing hormone agonist protocol for patients with a history of poor in vitro fertilization outcomes.
    Weitzman VN; Engmann L; DiLuigi A; Maier D; Nulsen J; Benadiva C
    Fertil Steril; 2009 Jul; 92(1):226-30. PubMed ID: 18675961
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Menstrual cycle synchronization, ovarian stimulation, and in vitro fertilization in olive baboons (Papio anubis): a prospective randomized study.
    Nyachieo A; Spiessens C; Chai DC; Mwenda JM; D'Hooghe TM
    Fertil Steril; 2009 Feb; 91(2):602-10. PubMed ID: 18328482
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Is the modified natural in vitro fertilization cycle justified in patients with "genuine" poor response to controlled ovarian hyperstimulation?
    Kedem A; Tsur A; Haas J; Yerushalmi GM; Hourvitz A; Machtinger R; Orvieto R
    Fertil Steril; 2014 Jun; 101(6):1624-8. PubMed ID: 24680364
    [TBL] [Abstract][Full Text] [Related]  

  • 33. GnRH antagonist, cetrorelix, for pituitary suppression in modern, patient-friendly assisted reproductive technology.
    Tur-Kaspa I; Ezcurra D
    Expert Opin Drug Metab Toxicol; 2009 Oct; 5(10):1323-36. PubMed ID: 19761413
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ovarian stimulation by concomitant administration of cetrorelix acetate and HMG following Diane-35 pre-treatment for patients with polycystic ovary syndrome: a prospective randomized study.
    Hwang JL; Seow KM; Lin YH; Huang LW; Hsieh BC; Tsai YL; Wu GJ; Huang SC; Chen CY; Chen PH; Tzeng CR
    Hum Reprod; 2004 Sep; 19(9):1993-2000. PubMed ID: 15284212
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ultrashort gonadotropin-releasing hormone agonist combined with flexible multidose gonadotropin-releasing hormone antagonist for poor responders in in vitro fertilization/embryo transfer programs.
    Orvieto R; Kruchkovich J; Rabinson J; Zohav E; Anteby EY; Meltcer S
    Fertil Steril; 2008 Jul; 90(1):228-30. PubMed ID: 17681292
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of gonadotropin-releasing hormone agonists and antagonists in assisted reproduction cycles of polycystic ovarian syndrome patients.
    Hosseini MA; Aleyasin A; Saeedi H; Mahdavi A
    J Obstet Gynaecol Res; 2010 Jun; 36(3):605-10. PubMed ID: 20598044
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ovarian stimulation with daily late follicular phase administration of low-dose human chorionic gonadotropin for in vitro fertilization: a prospective, randomized trial.
    Serafini P; Yadid I; Motta EL; Alegretti JR; Fioravanti J; Coslovsky M
    Fertil Steril; 2006 Oct; 86(4):830-8. PubMed ID: 16963040
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Controlled ovarian hyperstimulation using multi-dose gonadotropin-releasing hormone (GnRH) antagonist results in less systemic inflammation than the GnRH-agonist long protocol.
    Orvieto R; Volodarsky M; Hod E; Homburg R; Rabinson J; Zohav E; Anteby EY; Meltcer S
    Gynecol Endocrinol; 2007; 23(8):494-6. PubMed ID: 17852411
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of GnRH antagonist with long GnRH agonist protocol after OCP pretreatment in PCOs patients.
    Tehraninejad ES; Nasiri R; Rashidi B; Haghollahi F; Ataie M
    Arch Gynecol Obstet; 2010 Sep; 282(3):319-25. PubMed ID: 20379731
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fixed Gonadotropin-Releasing Hormone Antagonist Protocol
    Dong M; Sun L; Huang L; Wang F; Zhang X; Liu F
    Front Endocrinol (Lausanne); 2021; 12():690575. PubMed ID: 34867773
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.